Side effects usually diminish as the body adjusts to the medication
47x elevated NAION risk in clinical trial findings Wegovy lawsuit : Semaglutide FDA-approved for weight loss
In addition to acting through the p38 pathway, GLP-1RAs also promote the increase of PKA levels via the cAMP-dependent pathway, which in turn prevents the phosphorylation of epidermal growth factor receptor (EGFR) and activator of transcription 3 (STAT3), resulting in the inactivation of the EGFR-STAT3 signaling pathway in tumor cells and subsequently downregulating several downstream effector genes such as myelocytomatosis oncogene (c-Myc), survivin, cyclin D1, Bcl-xl, and Bcl-2, thereby inducing apoptosis in tumor cells in a dose-dependent manner [70, 73]
The timing can vary, but many find administering in the morning or before exercise convenient
Despite the lower weight loss cost, the drug has been shown to be far less effective than semaglutide variants